The use of amantadine sulfate in ischemic stroke

Ramazanov G.R.

Sklifosovsky Research Institute for Emergency Care

Kovaleva E.A.

Sklifosovsky Research Institute for Emergency Medicine

Shevchenko E.V.

Sklifosovsky Research Institute for Emergency Medicine

SPIN RSCI: 6658-4416
Scopus AuthorID: 57190116013
ORCID: 0000-0003-4200-1354

Akhmatkhanova L.Kh-B.

Sklifosovsky Research Institute for Emergency Medicine

The use of amantadine sulfate in ischemic stroke

Authors:

Ramazanov G.R., Kovaleva E.A., Shevchenko E.V., Akhmatkhanova L.Kh-B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12‑2): 56‑59

DOI: 10.17116/jnevro202012012256

Downloaded: 106

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Ramazanov GR, Kovaleva EA, Shevchenko EV, Akhmatkhanova LKh-B. The use of amantadine sulfate in ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12‑2):56‑59. (In Russ.)
https://doi.org/10.17116/jnevro202012012256

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Close metadata

OBJECTIVE

To assess the efficacy and safety of amantadine sulfate in patients with ischemic stroke.

MATERIAL AND METHODS

Ninety five patients with ischemic stroke were randomized within 120 hours from the onset of symptoms into two groups: patients of the main group received amantadine sulfate (400 mg/day intravenously) for 4 days, followed by oral administration at 400 mg/day for 6 days; the comparison group received standard therapy according to the order of the Ministry of Health of the Russian Federation No. 928n. The observation period for the patients was 90 days. The main indicators of treatment efficacy were: Glasgow Coma Scale (GCS), Modified Rankin Scale (mRS), Bartel Index (BI), National Institutes of Health Stroke Scale (NIHSS), and mortality. Any side effects were recorded to assess safety.

RESULTS AND CONCLUSION

There were no statistically significant differences between the main group and the comparison group for the main parameters. However, we observed better results in patients with mild stroke (NIHSS <13 points) and atherothrombotic pathogenetic variant of ischemic stroke. This observation should be confirmed in subsequent clinical studies.

Keywords:

amantadine sulfate

ischemic stroke

neuroprotector

Authors:

Ramazanov G.R.

Sklifosovsky Research Institute for Emergency Care

Kovaleva E.A.

Sklifosovsky Research Institute for Emergency Medicine

Shevchenko E.V.

Sklifosovsky Research Institute for Emergency Medicine

SPIN RSCI: 6658-4416
Scopus AuthorID: 57190116013
ORCID: 0000-0003-4200-1354

Akhmatkhanova L.Kh-B.

Sklifosovsky Research Institute for Emergency Medicine

Received:

07.09.2020

Accepted:

05.10.2020

List of references:

Fisher M, Dávalos A, Rogalewski A, Schneider A, Ringelstein EB, Schäbitz W-R. Toward a Multimodal Neuroprotective Treatment of Stroke. Stroke. 2006;37:1129-1136. https://doi.org/10.1161/01.STR.0000209330.73175.34
Skoromec AA, Stahovskaja LV, Belkin AA, Shehovcova KV, Kerbikov OB, Burenchev DV, Gavrilova OV, Skvorcova VI. Novye vozmozhnosti nejroprotekcii v lechenii ishemicheskogo insul’ta. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2008;108(S22):32-38. (In Russ.).
Rumjanceva SA, Benevol’skaja NG. Novye napravlenija v patogeneticheskoj terapii insul’ta. Atmosfera. Nervnye Bolezni: Zhurnal Dlja Prakticheskih Vrachej. 2006;4:29-34. (In Russ.).
Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005;25(13):3312-3322. https://doi.org/10.1523/JNEUROSCI.4262-04.2005
Saniova B, Drobny M, Lehotsky J, Sulaj M. Biochemical and clinical improvement ofcytotoxic state by amantadine sulphate. Cell Mol Neurobi. 2006;26(7-8):1475-1482.
Gomazkov OA. Nejrohimija ishemicheskih i vozrastnyh patologij mozga. M. 2003. (In Russ.).
Belkin AA, Shhegolev AB, Kondrat’ev AN, Bubnova ID. Ispol’zovanie amantadina sul’fata (PK-Merc) v period vyhoda iz komy: rezul’taty mnogocentrovogo issledovanija. Anesteziologija i Reanimatologija. 2008;2:70-72. (In Russ.).
Belkin AA, Shhegolev AV, Bel’skij DV, Vol AE, Domanskij DS, Pochepko DV, Istomin VV, Kondrat’ev AN, Borovikova VN, Surkov MV, Bubnova ID, Lesteva NA, Maleshina NI, Nazarov RA, Cenciper VM, Shestov AV, Kondrat’eva EA, Tukmarova RR, Alasheev AM. PK-Merc pri vegetativnom statuse i «malom soznanii». Intensivnaja Terapija. 2008;5(61):15-19. (In Russ.).
Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz D, Cho S, Yablon SA, Luther M, Hammond FM, Nordenbo A, Novak P, Mercer W, Maurer-Karattup P, Sherer M. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366(9):819-826. https://doi.org/10.1056/NEJMoa1102609
Culmsee C, Junker V, Kremers W, Thal S, Plesnila N, Krieglstein J. Combination Therapy in Ischemic Stroke: Synergistic Neuroprotective Effects of Memantine and Clenbuterol. Stroke. 2004;35(5):1197-1202. https://doi.org/10.1161/01.STR.0000125855.17686.6d
Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol. 1989;46(6):660-662. https://doi.org/10.1001/archneur.1989.00520420080026
Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil. 2002;17(4):300-313. https://doi.org/10.1097/00001199-200208000-00004
Schneider WN, Drew-Cates J, Wong TM, Dombovy ML. Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study. Brain Inj. 1999;13(11):863-872. https://doi.org/10.1080/026990599121061
Steube D, Gortelmeyer R. The influence of amantadine sulfate on disturbances of arousal after severe traumatic brain injury. Neurologe und Rehabilitation. 2000;6(6):307-312.
Wang T, Huang XJ, Van KC, Went GT, Nguyen JT, Lyeth BG. Amantadine improves cognitive outcome and increases neuronal survival after fluid percussion traumatic brain injury in rats. J Neurotrauma. 2014;31(4):370-377. https://doi.org/10.1089/neu.2013.2917
Hasanova DR, Sajhunov MV, Kitaeva EA, Hafiz’janova RH, Islamov RR, Demin TV. Amantadin sul’fat (PK-Merc) v lechenii ishemicheskogo insul’ta (kliniko-jeksperimental’noe issledovanie). Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2009;109(5-2):37-43. (In Russ.).
Krivonos OV, Amosova NA, Smolentseva IG. Use of the Glutamate NMDA Receptor Antagonist PK-Merz in Acute Stroke. Neurosci Behav Physiol. 2010;40(5):529-532. https://doi.org/10.1007/s11055-010-9292-6

Close metadata